Clinical trial
Xcellerated T CellsTM for Non-Hodgkin's Lymphoma (NHL) Patients
NCT00081783 · Xcyte Therapies, Industry · Unknown status
Key facts
| NCT number | NCT00081783 |
|---|---|
| Title | Xcellerated T CellsTM for Non-Hodgkin's Lymphoma (NHL) Patients |
| Official title | A Phase II Study of Xcellerated T CellsTM in Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma (NHL) |
| Lead sponsor | Xcyte Therapies, Industry |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Non-Hodgkin's Lymphoma |
| Intervention type | Drug |
| Interventions | Xcellerated T Cells |
| Enrollment | 40 |
| Start date | Mar 1, 2004 |
| First posted | Apr 22, 2004 |
| Last update posted | Jun 24, 2005 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- 100–999 FDA inspections linked to this trial
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: